Document is current

Article History

Received: 3 March 2025

Revised: 10 June 2025

Accepted: 1 August 2025

First Online: 5 September 2025

Competing interests

: AV: Honoraria from Beigene, AstraZeneca, Pfizer, Amgen, Jazz, AbbVie, Astellas, and Janssen; consulting/advisory role for BMS-Celgene, Istituto Gentili, Kyte-Gilead, Menarinini-Steamline, Glycostem, Servier, Laboratoires Delbert, Novartis, AbbVie, Pfizer, Jazz, and Janssen; speakers’ bureau participation for Pfizer and Servier; travel support from Jazz, Pfizer, AbbVie, Istituto Gentili, and Janssen. J-ZH: Consulting/advisory role for AbbVie, AstraZeneca, and Genentech. PF: Consultancy/advisory role for Bristol Myers Squibb, AbbVie, Janssen, Jazz, and Novartis; research support, as GFM chair, from Bristol Myers Squibb, AbbVie, Janssen, Jazz, and Novartis; honoraria from Bristol Myers Squibb, AbbVie, Janssen, Jazz, and Novartis. BAJ: Consultancy/advisory role for AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Genentech, Gilead, GlycoMimetics, Kymera, Kura, Rigel, Schrodinger, Servier, Syndax, and Treadwell; protocol steering committee for GlycoMimetics; data monitoring committee for Gilead; travel reimbursement from AbbVie and Rigel; research funding to institution from AbbVie, Amgen, Aptose, AROG, Biomea, Bristol Myers Squibb, Celgene, Daiichi Sankyo, F. Hoffmann‑La Roche, Forma, Forty‑Seven, Genentech/Roche, Gilead, GlycoMimetics, Hanmi, Immune‑Onc, Incyte, Jazz, Kymera, Loxo, Pfizer, Pharmacyclics, Sigma Tau, and Treadwell. RV: Honoraria from AbbVie, Astellas, MSD, Novartis, Pfizer, PharmaS, Servier, Teva; speakers’ bureau participation for AbbVie, Astellas, Pfizer, and PharmaS. PM: Consultancy/advisory role for Celgene, Pfizer, and AbbVie; research funding from Pfizer, AbbVie, and Daiichi Sankyo; speakers’ bureau participation for Astellas, Novartis, and Janssen. JSG: Advisory role for AbbVie, Astellas, Bristol Myers Squibb, Genentech, Gilead and Servier. Institutional funding from AbbVie, Genentech, New Wave, Prelude, Pfizer, and AstraZeneca. DR: Speakers’ bureau participation for and honoraria from AbbVie. MJT: Grant support, consulting fees, and advisory board fees from AbbVie, Roche‑Genentech, Janssen, and Pharmacyclics; grant support from Gilead Sciences, Merck, Syndax Pharmaceuticals, TG Therapeutics, and Tolero Pharmaceuticals; and consulting fees and advisory board fees from AstraZeneca and Celgene. MZ, JP, CM, and MD: Employment with AbbVie; may hold stock or other options. VP: Advisory board fees and fees for serving on a speaker’s bureau from AbbVie, Genentech, Pfizer, Jazz, Novartis, Servier, and Amgen.